PROGENSA PCA3 Assay Approved to Help Determine if Repeat Prostate Biopsy is Warranted

Share this content:
PROGENSA PCA3 Assay Approved to Help Determine if Repeat Prostate Biopsy is Warranted
PROGENSA PCA3 Assay Approved to Help Determine if Repeat Prostate Biopsy is Warranted

(ChemotherapyAdvisor) – The U.S. Food and Drug Administration has approved PROGENSA PCA3, “the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy,” according to the assay's manufacturer, Gen-Probe, San Diego, CA.

The PROGENSA PCA3 assay is an in vitro nucleic acid amplification test that detects Prostate Cancer Gene 3 (PCA3) messenger ribonucleic acid in male urine specimens following a digital rectal examination. These results are used to generate a PCA3 score: the higher the score, the higher the likelihood of a positive biopsy. The PCA3 score is intended for use in conjunction with standard-of-care diagnostic algorithms as an aid in the diagnosis of prostate cancer.

A multicenter clinical study of PROGENSA PCA3 in 495 men recommended for repeat biopsy found the assay had a negative predictive value of 90%.

The PROGENSA PCA3 assay should not be used for men with atypical small acinar proliferation on their most recent biopsy; instead, these men should be treated following current medical guidelines. Assay performance has not been established in men for whom a repeat biopsy is not recommended.

Photo credit: FDA-approved PROGENSA PCA3 test helps determine need for repeat prostate biopsy. (PRNewsFoto/Gen-Probe Incorporated)

Clinical Trial

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs